Vamorolone

伐莫洛龙

Report date: 2026/01/16 17:44:37
NME

Base Information

Drug NameVamorolone
Drug Alias Namevamorolona伐莫龙vamorolonumvamoroloneAGAMREE +[10] 
ClassificationSmall molecules > Steroids
Mechanisms of ActionGlucocorticoid receptor agonistsMineralocorticoid receptor antagonists
TargetsGlucocorticoid receptorMineralocorticoid receptor
Therapy Area/IndicationsPediatric ulcerative colitisBecker muscular dystrophyMuscular Dystrophy, Duchenne
Global Approved IndicationsMuscular Dystrophy, Duchenne
Approved Indications in ChinaMuscular Dystrophy, Duchenne
Original Approved Country/TerritoryUnited States
Original Approved Date2023/10/26
Country/TerritoryCzechiaBelgiumCanada +[16] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesReveragen Biopharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesSanthera PharmaceuticalsCatalystNxera Pharma UK Ltd +[10] 
Inactive CompaniesPurna Pharmaceuticals Nv/SaSperogenix（Shanghai）Med Tech Co LtdSanthera Pharmaceuticals (Switzerland) Ltd
Active IndicationsBecker muscular dystrophyMuscular Dystrophy, Duchenne
Inactive IndicationsPediatric ulcerative colitis

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG